20-HEDE
Based on 2 publication(s) in Google Scholar
20-HEDE (WIT 002) is an antagonist of 20-hydroxyeicosatetraenoic acid (20-HETE).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 97.11%
- CAS No.: 240427-90-1
- Formule: C20H36O3
- Masse moléculaire:324.50
-
Stockage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) 20-HEDE
More
Activité biologique
20-HEDE (WIT 002)[1].
ω-hydroxylation activity toward arachidonic acid is high in A549 cells, thus, A549 cells are treated with HET0016 or WIT 002 in the invasion assays, and both of them significantly decrease invasion[2]. WIT 002 inhibits proliferation of 786-O and 769-P renal adenocarcinoma cells, but HET0016 and WIT 002 fail to inhibit proliferation of normal renal epithelial cells RPTC[2][3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 240427-90-1
-
Appearance Liquid (Density: 0.959±0.06 g/cm3)
-
Masse moléculaire 324.50
-
Formule C20H36O3
-
Color Colorless to light yellow
-
SMILES
O=C(O)CCCC/C=C\CCCCCCC/C=C\CCCCO
-
Synonyms
WIT 002
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
Solvant et solubilité
DMSO : 100 mg/mL (308.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.70 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.70 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Human NSCLC cell lines (e.g A549) are seeded onto the upper well of the chamber. Subsequently, serum-free medium with HET0016 (10 μM), WIT002 (10 μM), WIT003 (0.01, 0.1, 1 μM), or ethanol as a control is added to the upper chamber, while the lower well is filled to the top (500 μL) with RPMI-1640 containing 5% fetal calf serum (FCS) as a chemoattractant. Cells are allowed to migrate for 5 h. Cells that have invaded to the bottom surface of the filter are counted with an ocular micrometer in a blinded manner, counting a minimum of 10 high-powered fields (HPF) [2]. Human renal cell adenocarcinoma lines (RPTC) 786-O or 769-P cells are plated and next day (0 hrs) transferred to serum-free medium containing either EGF or ET-1. Cells are exposed either to 10 μM WIT002 or vehicle. Cell counting is performed at the day of transfer to serum free medium (0 hrs) and 24, 48 and 72 hrs thereafter. Medium is changed to fresh containing mitogens and drugs every 24 hrs. Data presented are characteristic experiment from at least two separate experiments, each performed in triplicate[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[3]
Experiments are carried out on 6-week immunodefficient athymic nude mice weighing 20-26 g. Animals are acclimated for 1 week prior to injection with renal cell carcinoma. Immediately before each implantation, the cells are trypsinized, counted and resuspended in 10% serum containing RPMI media. The concentration of cells is adjusted to 40 millions/mL and 4 million cells/animal are injected subcutaneously. The cells are allowed to grow for 7-15 days until the size of the tumors reach approximately 0.1 cm3. The mice then receive daily subcutaneous injection (s.c.) injections of WIT 002 (10 mg/kg/day in 200 μL) in an isotonic NaPO4 buffer (pH 9.0) or vehicle (0.1 M NaPO4 solution pH 9.0). The diameter of the tumor is measured on every 3-4 days for 2 weeks using precision calibers. At the end of the experiment the mice are euthanized with CO2 and the tumors were excised to confirm the diameter measurements[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ming Yua . et al. Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol. 2004 Feb 23;486(3):297-306. [Content Brief]
[2]. Wei Yu, et al. Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer. Cancer Chemother Pharmacol. 2011 Sep; 68(3): 619-29. [Content Brief]
[3]. Anna Alexanian, et al. Down-regulation of 20-HETE Synthesis and Signaling Inhibits Renal Adenocarcinoma Cell Proliferation and Tumor Growth. Anticancer Res. 2009 October ; 29(10): 3819-3824. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0817 mL | 15.4083 mL | 30.8166 mL | 77.0416 mL |
| 5 mM | 0.6163 mL | 3.0817 mL | 6.1633 mL | 15.4083 mL | |
| 10 mM | 0.3082 mL | 1.5408 mL | 3.0817 mL | 7.7042 mL | |
| 15 mM | 0.2054 mL | 1.0272 mL | 2.0544 mL | 5.1361 mL | |
| 20 mM | 0.1541 mL | 0.7704 mL | 1.5408 mL | 3.8521 mL | |
| 25 mM | 0.1233 mL | 0.6163 mL | 1.2327 mL | 3.0817 mL | |
| 30 mM | 0.1027 mL | 0.5136 mL | 1.0272 mL | 2.5681 mL | |
| 40 mM | 0.0770 mL | 0.3852 mL | 0.7704 mL | 1.9260 mL | |
| 50 mM | 0.0616 mL | 0.3082 mL | 0.6163 mL | 1.5408 mL | |
| 60 mM | 0.0514 mL | 0.2568 mL | 0.5136 mL | 1.2840 mL | |
| 80 mM | 0.0385 mL | 0.1926 mL | 0.3852 mL | 0.9630 mL | |
| 100 mM | 0.0308 mL | 0.1541 mL | 0.3082 mL | 0.7704 mL |
20-HEDE Related Classifications
HY-101527 Related Classifications
Powered by Bioz